Serum IgG Responses against Aspergillus Proteins before Hematopoietic Stem Cell Transplantation or Chemotherapy Identify Patients Who Develop Invasive Aspergillosis

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 12, 2012, Pages 1927-1934

  Du, Chen ^a   Wingard, John R ^b   Cheng, Shaoji ^a   Nguyen, M Hong ^a   Clancy, Cornelius J ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antibody; Diagnosis; Invasive fungal infections

Indexed keywords

CELL CYCLE PROTEIN 37; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; ENOLASE; FUNGAL PROTEIN; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN AHP 1; PROTEIN PEP 2; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; FUNGAL COLONIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; NONHUMAN; PATIENT IDENTIFICATION; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SCREENING TEST; TREATMENT RESPONSE;

ACUTE DISEASE; ASPERGILLOSIS; ASPERGILLUS; FUNGAL PROTEINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; LEUKEMIA; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS;

EID: 84869092591     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.07.013     Document Type: Article

References (47)

1. Fukuda T., Boeckh M., Carter R.A., et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003, 102:827-833.
2. Grow W.B., Moreb J.S., Roque D., et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002, 29:15-19.
3. Marr K.A., Carter R.A., Boeckh M., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100:4358-4366.
4. Patterson T.F., Kirkpatrick W.R., White M., et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000, 79:250-260.
5. Lin S.J., Schranz J., Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001, 32:358-366.
6. Greene R.E., Mauskopf J., Roberts C.S., et al. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis. Am J Health Syst Pharm 2007, 64:2561-2568.
7. von Eiff M., Roos N., Schulten R., et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995, 62:341-347.
8. Maertens J., Verhaegen J., Lagrou K., et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001, 97:1604-1610. for the I3 Aspergillus Study Group.
9. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335-347.
10. Wingard J.R., Carter S.L., Walsh T.J., et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010, 116:5111-5118.
11. Cunha C., Giovannini G., Pierini A., et al. Genetically-determined hyperfunction of the S100B/RAGE axis is a risk factor for aspergillosis in stem cell transplant recipients. PLoS One 2011, 6:e27962.
12. Cunha C., Di Ianni M., Bozza S., et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 2010, 116:5394-5402.
13. Kesh S., Mensah N.Y., Peterlongo P., et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann NY Acad Sci 2005, 1062:95-103.
14. Bochud P.Y., Chien J.W., Marr K.A., et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008, 359:1766-1777.
15. Sarfati J., Monod M., Recco P., et al. Recombinant antigens as diagnostic markers for aspergillosis. Diagn Microbiol Infect Dis 2006, 55:279-291.
16. Wingard J.R., Ribaud P., Schlamm H.T., et al. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008, 112:2309-2312.
17. De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
18. Segal B.H., Herbrecht R., Stevens D.A., et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008, 47:674-683.
19. Denikus N., Orfaniotou F., Wulf G., et al. Fungal antigens expressed during invasive aspergillosis. Infect Immun 2005, 73:4704-4713.
20. Lai H.Y., Tam M.F., Tang R.B., et al. cDNA cloning and immunological characterization of a newly identified enolase allergen from Penicillium citrinum and Aspergillus fumigatus. Int Arch Allergy Immunol 2002, 127:181-190.
21. Crameri R., Hemmann S., Ismail C., et al. Disease-specific recombinant allergens for the diagnosis of allergic bronchopulmonary aspergillosis. Int Immunol 1998, 10:1211-1216.
22. Hemmann S., Blaser K., Crameri R. Allergens of Aspergillus fumigatus and Candida boidinii share IgE-binding epitopes. Am J Respir Crit Care Med 1997, 156:1956-1962.
23. Hemmann S., Nikolaizik W.H., Schoni M.H., et al. Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. Eur J Immunol 1998, 28:1155-1160.
24. Burnie J.P. Antigen detection in invasive aspergillosis. J Immunol Methods 1991, 143:187-195.
25. Centeno-Lima S., de Lacerda J.M., do Carmo J.A., et al. Follow-up of anti-Aspergillus IgG and IgA antibodies in bone marrow-transplanted patients with invasive aspergillosis. J Clin Lab Anal 2002, 16:156-162.
26. Matthews R.C., Rigg G., Hodgetts S., et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003, 47:2208-2216.
27. Burnie J., Matthews R. The role of antibodies against hsp90 in the treatment of fungal infections. Drug News Perspect 2003, 16:205-210.
28. Pachl J., Svoboda P., Jacobs F., et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006, 42:1404-1413.
29. Louie A., Stein D.S., Zack J.Z., et al. Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis. Antimicrob Agents Chemother 2011, 55:3295-3304.
30. Montagnoli C., Sandini S., Bacci A., et al. Immunogenicity and protective effect of recombinant enolase of Candida albicans in a murine model of systemic candidiasis. Med Mycol 2004, 42:319-324.
31. van Deventer H.J., Goessens W.H., van Vliet A.J., et al. Anti-enolase antibodies partially protective against systemic candidiasis in mice. Clin Microbiol Infect 1996, 2:36-43.
32. Hohl T.M., Feldmesser M. Aspergillus fumigatus: principles of pathogenesis and host defense. Eukaryot Cell 2007, 6:1953-1963.
33. Marr K.A. Fungal infections in hematopoietic stem cell transplant recipients. Med Mycol 2008, 46:293-302.
34. Chazalet V., Debeaupuis J.P., Sarfati J., et al. Molecular typing of environmental and patient isolates of Aspergillus fumigatus from various hospital settings. J Clin Microbiol 1998, 36:1494-1500.
35. Arnow P.M., Andersen R.L., Mainous P.D., et al. Pulmonary aspergillosis during hospital renovation. Am Rev Respir Dis 1978, 118:49-53.
36. Aisner J., Schimpff S.C., Bennett J.E., et al. Aspergillus infections in cancer patients: association with fireproofing materials in a new hospital. JAMA 1976, 235:411-412.
37. Arnow P.M., Sadigh M., Costas C., et al. Endemic and epidemic aspergillosis associated with in-hospital replication of Aspergillus organisms. J Infect Dis 1991, 164:998-1002.
38. Barnes R.A., Rogers T.R. Control of an outbreak of nosocomial aspergillosis by laminar air-flow isolation. J Hosp Infect 1989, 14:89-94.
39. Sherertz R.J., Belani A., Kramer B.S., et al. Impact of air filtration on nosocomial Aspergillus infections: unique risk of bone marrow transplant recipients. Am J Med 1987, 83:709-718.
40. Vonberg R.P., Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect 2006, 63:246-254.
41. Patterson J.E., Peters J., Calhoon J.H., et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis 2000, 2:22-28.
42. Bennett J.E., Bhattacharjee A.K., Glaudemans C.P. Galactofuranosyl groups are immunodominant in Aspergillus fumigatus galactomannan. Mol Immunol 1985, 22:251-254.
43. Schaefer J.C., Yu B., Armstrong D. An Aspergillus immunodiffusion test in the early diagnosis of aspergillosis in adult leukemia patients. Am Rev Respir Dis 1976, 113:325-329.
44. Matthews R., Burnie J.P., Fox A., et al. Immunoblot analysis of serological responses in invasive aspergillosis. J Clin Pathol 1985, 38:1300-1303.
45. Bergeron A., Porcher R., Menotti J., et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J Clin Microbiol 2012, 50:823-830.
46. Cowen L.E., Singh S.D., Kohler J.R., et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci USA 2009, 106:2818-2823.
47. Vadnerkar A., Clancy C.J., Celik U., et al. Impact of mold infections in explanted lungs on outcomes of lung transplantation. Transplantation 2010, 89:253-260.